GlassScriptPhysician profile
Noel P Lim
NPI 1710919295
$5,056.34
in general payments reported to CMS, 2019-2025
34 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.24 · 2022: $1,290 · 2023: $1,453 · 2024: $1,117 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,502.29 | 2021-2025 | |
| Ucb, INC. | $456.90 | 2022-2025 | Briviact |
| Neurocrine Biosciences, INC. | $425.94 | 2022-2025 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $235.45 | 2022-2025 | Nuplazid |
| Lundbeck LLC | $226.72 | 2023-2025 | Vyepti, Rexulti |
| Ani Pharmaceuticals, INC. | $205.46 | 2022-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $203.55 | 2022-2025 | |
| Genzyme Corporation | $176.15 | 2022-2023 | |
| Sk Life Science, INC. | $175.64 | 2023-2025 | |
| Emd Serono, INC. | $157.14 | 2022-2025 | Mavenclad |
| Biogen, INC. | $148.93 | 2022-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $147.25 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $121.12 | 2022-2025 | Ultomiris |
| Avanir Pharmaceuticals, INC. | $108.51 | 2022 | |
| Csl Behring | $90.36 | 2024-2025 | Hizentra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $88.44 | 2025 | Vyvgart Hytrulo |
| Mdd US Operations, LLC | $87.68 | 2023-2025 | Gocovri |
| Boston Scientific Corporation | $82.68 | 2023 | |
| Sumitomo Pharma America, INC. | $72.02 | 2023-2024 | Aptiom |
| Amgen INC. | $66.96 | 2022-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $46.42 | 2023-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $22.20 | 2022 | |
| Tg Therapeutics, INC. | $21.50 | 2024 | |
| Axsome Therapeutics, INC. | $21.22 | 2025 | Symbravo |
| Cycle Pharmaceuticals INC | $20.53 | 2024 | Tascenso Odt |
| Pfizer INC. | $19.73 | 2025 | |
| Eisai INC. | $18.90 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.96 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $16.22 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.13 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.67 | 2025 | Onpattro |
| Banner Life Sciences, LLC | $14.31 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.00 | 2021 | |
| Neurelis, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.